Current prevalence of falciparum malarial infection among HIV patients on highly active antiretroviral therapy in university of Uyo teaching hospital, Uyo Nigeria
DOI:
https://doi.org/10.18203/2320-6012.ijrms20183627Keywords:
Current Prevalence, falciparum, HIV Patients, HAARTAbstract
Background: Malaria and HIV remain two leading causes of morbidity and mortality to patients in developing African countries. Both infectious diseases have been documented to account for an enormous morbidity and mortality in Sub-Saharan Africa. The geographical overlap in sub-Saharan Africa and South America has led to similarities in co-infection with Plasmodium and HIV, this has resulted in the quick progression and severity of both diseases particularly among the poor, and contributes to the poverty of sub-Saharan African nations by taking a toll on young people who contribute greatly to the workforce of the economy. The present study was conducted to determine the prevalence of malarial infection in HIV patients receiving high active antiretroviral therapy in university Uyo teaching hospital, Uyo Nigeria.
Methods: A predesigned structured questionnaire was administered to collect bio data and socio-demographic characteristics from the participants consisting 35 HIV infected adult patients and 32 non HIV infected adults as controls. All HIV patients were receiving HAART during this study. The HAART regimens used by HIV infected patients consist of zidovudine, lamivudine, efavirenze, and nevirapine.
Results: About 5 (14.2%) HIV patients on HAART had falciparum malaria. No falciparum malaria was detected in HIV negative participants. Of the five positive malaria cases detected in HIV patients, 8.5% were females and 5.7% were males.
Conclusions: There was no significant difference of malaria parasite infection by gender (P = 0.88), age group (P = 0.17), and CD4+ count (O.R:1.0, P = 0.81).
References
Jalousian F, Dalimi A, Samiee SM, Ghaffarifar F, Soleymanloo F, Naghizadeh R. Mutation in pfmdr1 gene in chloroquine-resistant Plasmodium falciparum isolates Southeast Iran. Int Soc for Infect Dis. 2008;12:630-4.
Blair C. Co-Morbidity of HIV and Malaria in Sub-Saharan Africa. 2015: Available at https.//mcstor.library.milligan.edu.
Averting HIV and AIDS. HIV and Aids in sub-Saharan Africa regional overview. 2016. Available at: www.avert.org/professionals/hiv-around-world/ sub-saharan-africa/overview#footnote1_yaiska7. Accessed 23 July 2016.
United Nations Programme on HIV/AIDS. The Gap report. 2014. Available at: www.unaids.org/UNAIDS_Gap_report. Accessed 22 September 2016.
Hochman S, Kim K. The impact of HIV and Malaria co-infection: What is known and suggested viruses for further study. Interdiscip Perspect Infect Dis. 2009;10:1-4.
Akinbo FO, Anate PJ, Akinbo DB, Omoregie R, Okoosi S, Abdulsalami, et al. Prevalence of malaria among HIV patients on highly active antiretroviral therapy in Kogi State North Central Nigeria. Ann Nigerian Med. 2016;10:1.
Nwauche CI. Use of artemether-lumefantrine in the treatment of asymptomatic-malaria infection in HIV -positive and HIV negative Nigerian adults. 2014. Available at: http://researchonline.lshtm.ac.uk/ 1856059/. Accessed 29 September 2017.
Nakanjako D, Kiragga AN, Castelnuovo B, Kyabayinze DJ, Kamya MR. Low prevalence of Plasmodium falciparum antigenaemia among asymptomatic HAART treated adults in an urban cohort in Uganda. Mal J. 2011;10:66.
Akinbo FO, Omoregie R. Plasmodium falciparum infection in HIV infected patients on highly active antiretroviral therapy (HAART) in Benin City, Nigeria. J Res Health Sci. 2012;12:158.
Uni-gold. Procedure for HIV testing. 2017. Available at: http//trinitybitech.com/area/uni-gold/. Accessed 14 July 2017.
University of Uyo Teaching Hospital Safety Operation Procedure. CD4 T-cell enumeration 2016; Antretroviral therapy laboratory specimen testing. Document. ST-SOP-3.7-3.
Srinivas K. Malaria testing. 2015. Available at: malarasite.com/malariatesting/. Accessed 20 May 2016.
Zymo Research Corp. Protocol manual quick g-DNA TM MiniPrep Kit. 2016. Available at https://d2gsy6rsbfrvyb.cloudfront.net/media/amasty/amfile/attach/_D3024_D3025_Quick-DNA_ Miniprep_Kit_ver2.1.0.pdf. Accessed 17 September 2016.
United Nations Development Programme. Discussion Paper. Gender and Malaria “Making the investment case for programming that addresses the specific vulnerabilities and needs of both males and females who are affected by or at risk of malaria” 2015; Available at: http://www.undp.org/content/ dam/undp/library/HIV-AIDS/Gender%20HIV% 20and%20Health/Discussion%20Paper%20Gender_Malaria.pdf. Accessed 18 January 2017.
Wariso KT, Nwauche CA. The prevalence of malaria antigen in the serum of HIV sero-positive patients in Port Harcourt. Ng Health J. 2011;11:120 2.
Fehintola FA, Adewole IF, Maponga CC, Adewole IF, Qing MA, Morse, GD. Drug interaction in treatment and chemoprophylaxis of malaria in HIV infected individuals in Sub-saharan Africa. Curr Drug Metab. 2011;12(1):51-6.
